In what has been a busy year of innovators and generic companies sparring over how to foster a more competitive marketplace, the Association for Accessible Medicines (AAM) and the Pharmaceutical Research and Manufacturers of America (PhRMA) renewed their rivalry on the issue in comments to the US FDA.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?